Breathe Well Live Well
|
KaloBios Shares Slide on Move to Stop Asthma Treatment Study
Wall Street Journal KaloBios Pharmaceuticals Inc.'s (KBIO) shares slumped after the company said it would discontinue development of a treatment for severe asthma, a move that followed disappointing Phase 2 results. Chief Executive Officer David Pritchard said based on … |
View full post on asthma – Google News
 Reuters UK |
Glaxo on the slide after trials setback for asthma drug
Evening Standard But clinical trials have not shown the new treatment to be better than GSK's flagship asthma drug Advair. "The results aren't a home run but look adequate for filing and approval," said pharma analyst Emmanuel Papadakis at Collins Stewart. … GSK and Theravance Announce Initial Outcomes From Pivotal Phase III Studies … GSK to seek approval of Theravance lung drug For COPD, Glaxo intends to submit regulatory applications in the US and Europe … |
View full post on asthma – Google News